Definium's LSD Therapy Hits Goal in Phase 3 Depression Trial

Definium Therapeutics says its LSD-based drug, DT-120, helped patients with major depressive disorder in its first Phase 3 trial, according to STAT News. The result pushes the psychedelic closer to a potential regulatory submission and possible approval.

The finding matters because late-stage data is the threshold the FDA needs to consider clearing a new therapy. Most psychedelic research to date has been earlier-stage or focused on other compounds. A positive Phase 3 readout for LSD specifically signals that the science is maturing past small academic studies into the kind of large, controlled trials regulators require.

The field has had a rocky path. The FDA declined to approve MDMA-assisted therapy for PTSD, a high-profile setback that raised questions about trial design, blinding, and the role of accompanying psychotherapy. Definium's data will face the same scrutiny. Investors and clinicians will want to see the full results, including how durable the effect is and how the company handles dosing and supervision in practice.